Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral
Research Highlights:
In the 7-year, phase III, multicenter, international Lp(a) HORIZON trial, the novel medication pelacarsen lowered…
Browsing Tag